Adults with type 2 diabetes requiring insulin therapy can safely achieve good blood sugar control using regular human insulin (RHI) in a wearable, patch-like insulin delivery device called V-Go, a new study finds. Results of the randomized controlled study—which was accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and will be published in a special supplemental section of the Journal of the Endocrine Society—suggest "a more affordable option" for insulin therapy than newer insulin types, the researchers said.
* This article was originally published here
